RDNT vs. VCYT, FLGT, VRDN, PROG, CDNA, GH, NTRA, PCRX, ATEC, and FGEN
Should you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Veracyte (VCYT), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), Progenity (PROG), CareDx (CDNA), Guardant Health (GH), Natera (NTRA), Pacira BioSciences (PCRX), Alphatec (ATEC), and FibroGen (FGEN). These companies are all part of the "medical" sector.
RadNet vs.
RadNet (NASDAQ:RDNT) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.
In the previous week, RadNet had 4 more articles in the media than Veracyte. MarketBeat recorded 8 mentions for RadNet and 4 mentions for Veracyte. Veracyte's average media sentiment score of 0.76 beat RadNet's score of -0.12 indicating that Veracyte is being referred to more favorably in the news media.
RadNet currently has a consensus price target of $30.00, indicating a potential downside of 6.54%. Veracyte has a consensus price target of $30.20, indicating a potential upside of 16.87%. Given Veracyte's higher probable upside, analysts plainly believe Veracyte is more favorable than RadNet.
RadNet has higher revenue and earnings than Veracyte. RadNet is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
68.3% of RadNet shares are held by institutional investors. 4.4% of RadNet shares are held by insiders. Comparatively, 2.9% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
RadNet has a net margin of -0.90% compared to Veracyte's net margin of -9.70%. RadNet's return on equity of 3.28% beat Veracyte's return on equity.
RadNet has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Veracyte received 88 more outperform votes than RadNet when rated by MarketBeat users. Likewise, 73.14% of users gave Veracyte an outperform vote while only 67.20% of users gave RadNet an outperform vote.
Summary
RadNet beats Veracyte on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools